##国家医保局首次公开问询药械企业，Castor支架价格虚高引关注
**中新社北京8月21日电** 为治理价格虚高，维护医保基金安全，中国国家医疗保障局近日首次对药械企业公开问询，矛头直指上海微创心脉医疗科技(集团)股份有限公司(以下简称“心脉医疗”)生产的Castor胸主动脉覆膜支架及输送系统(以下简称“Castor支架”)价格虚高问题。
国家医保局公开问询函显示，经初步核实，Castor支架(200mm长度)出厂价格约为5万元，但经代理商供应医疗机构的价格却超过12万元，价差显著超出必要范围。尽管心脉医疗已提出价格调整计划，但国家医保局认为其并未改变价格风险，因此采取公开问询措施，要求该公司于8月26日前提交相关说明材料，并对外披露全部内容，接受社会监督和同行评议。
国家医保局强调，此举旨在规范经营者价格行为，维护正常价格秩序，防止利用流通环节过高费用进行不当营销，侵害患者和医保基金的合法权益。后续，国家医保局将根据医药价格风险处置机制，视情况对心脉医疗进行正式约谈，必要时按照医药价格和招采信用评价制度实施信用评级并采取相应处置措施。
值得注意的是，心脉医疗并非唯一被约谈的胸主动脉覆膜支架企业。国家医保局近期连续收到民众信访反映该类支架价格异常问题。由于药械挂网申报和定价主体为生产企业、上市许可持有人或进口总代理企业，国家医保局已直接约谈相关生产企业和进口总代理企业。目前，已有11家国内外企业结合出厂价格和竞争格局等因素，主动重新制定价格，各企业相关产品价格全部降至8万元以下。
此次国家医保局对药械企业公开问询，标志着医保部门在治理价格虚高方面迈出了重要一步，也释放出强烈的监管信号。专家认为，此举将有效遏制药械企业不合理定价行为，维护患者权益，促进医药市场健康发展。
英语如下：
##China’s Medical Insurance Bureau Publicly Questions Drug Company Over High Price ofCastor Stent
**Keywords:** Medical Insurance Inquiry, Price Inflation, Castor Stent
**Beijing, August 21 (CNS)** – In a move to combat price gouging and safeguard medical insurance funds, China’s National HealthcareSecurity Administration (NHSA) has publicly questioned a drug and medical device company for the first time, targeting the inflated price of the Castor thoracic aortic stent produced byShanghai MicroPort Medical (Group) Co., Ltd. (MicroPort Medical).
The NHSA’s public inquiry letter revealed that the factory price of the Castor stent (200mm length) is approximately 50,000 yuan, but the price supplied to medical institutions through distributors exceeds 120,000 yuan, with a significant price difference exceeding the necessary range. Although MicroPort Medical has proposed a price adjustment plan, the NHSAbelieves it does not address the price risk. Therefore, the NHSA has publicly questioned the company, demanding it submit relevant explanatory materials by August 26, disclose all content publicly, and accept social supervision and peer review.
The NHSA emphasized that this move aims to regulate the pricing behavior of operators, maintain anormal pricing order, prevent the use of excessive costs in the distribution chain for improper marketing, and protect the legitimate rights and interests of patients and medical insurance funds. Subsequently, the NHSA will formally interview MicroPort Medical based on the pharmaceutical price risk disposal mechanism, and if necessary, implement credit rating and take corresponding disposal measuresaccording to the pharmaceutical price and procurement credit evaluation system.
It is noteworthy that MicroPort Medical is not the only company being questioned about thoracic aortic stents. The NHSA has recently received numerous complaints from the public regarding abnormal pricing of such stents. As the drug and medical device listing declaration and pricing entities are themanufacturing companies, marketing authorization holders, or import agents, the NHSA has directly interviewed relevant manufacturing companies and import agents. Currently, 11 domestic and foreign companies have proactively adjusted their prices based on factory prices and competitive landscape, with all related product prices falling below 80,000 yuan.
TheNHSA’s public inquiry into drug and medical device companies marks a significant step in the medical insurance department’s efforts to combat price gouging and sends a strong regulatory signal. Experts believe this move will effectively curb unreasonable pricing practices by drug and medical device companies, protect patient rights, and promote healthy development of the pharmaceuticalmarket.
【来源】http://www.chinanews.com/cj/2024/08-21/10272625.shtml
Views: 1